SQUAREX
Squarex is a clinical-stage pharmaceutical company developing a drug and topical application to prevent infections. This application develops a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The company was founded in 2012 and is headquartered in Saint Paul, Minnesota.
SQUAREX
Industry:
Health Care Medical Pharmaceutical Wellness
Founded:
2012-01-01
Address:
Saint Paul, Minnesota, United States
Country:
United States
Website Url:
http://www.squarex-pharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Euro Cloudflare Hosting
Similar Organizations
Abfero Pharmaceuticals
Abfero Pharmaceuticals is a clinical stage pharmaceutical company that specializes in healthcare and medical industry.
Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company developing products for the treatment of glaucoma.
AEROGEN PHARMA
AEROGEN PHARMA is a clinical-stage specialty pharmaceutical company developing proprietary inhaled medications.
Affinivax
Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Metacrine
Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.
Perosphere
Perosphere is a private specialty pharmaceutical company developing rescue medications.
Current Employees Featured
Founder
Official Site Inspections
http://www.squarex-pharma.com
- Host name: 35.0.153.160.host.secureserver.net
- IP address: 160.153.0.35
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Squarex"
Squarex - Crunchbase Company Profile & Funding
Contact Email [email protected] Squarex is a clinical-stage pharmaceutical company developing a drug and topical application to prevent infections. This application develops a โฆSee details»
Improving immune system to prevent cold sores. Return - Squarex
Maybe the Only Opportunity in Pharma With: 1. Statistically Significant Efficacy in 3 of 3 clinical trials โข Phase 1, Phase 2, and Mechanism of Action clinical trials completed, all with significant โฆSee details»
Squarex Company Profile 2024: Valuation, Funding
Www.squarex-pharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 1000 Westgate Drive; Suite 1010; Saint Paul, MN 55114; United StatesSee details»
SquareX Pharmaceutical Corporation - LinkedIn
SquareX Pharmaceutical Corporation Pharmaceutical Manufacturing St Paul, Minnesota 109 followers We are developing a drug (topical immune stimulator) that prevents oral herpes or โฆSee details»
Squarex Announces End of Phase 2 Meeting with FDA โฆ
Saint Paul, Minnesota, USA, 19 January 2021 โ Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention โฆSee details»
Squarex, LLC: Preventing oral herpes with a topical โฆ
Squarex would be an attractive acquisition or licensing opportunity for large pharmaceutical companies, both pre-and post-approval and revenue of the Squarex lead drug. Partnering Squarex may partner with an established โฆSee details»
SquareX Overview
[email protected] Pre-IPO Stock O๏ฌering Potential 100x Return www.squarex-pharma.com SquareX Overview $22 million pre-money valuation. $3.00 per share, Estimated โฆSee details»
St. Paul-based Squarex Withdraws IPO Plans - Twin โฆ
May 22, 2023 A St. Paul biotech company run by one-time gubernatorial candidate Hugh McTavish has shelved plans to go public, for now. On Friday, Squarex Pharmaceuticals Corp. submitted paperwork asking the U ...See details»
Squarex Pharmaceutical Seeks IPO For Development โฆ
Jan 23, 2023 Squarex Pharmaceutical Corporation has filed to raise $17.8 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a biopharma developing a treatment for ...See details»
Squarex Announces End of Phase 2 Meeting with FDA for its Cold โฆ
Jan 19, 2021 Squarex announces that is has completed an End-of-Phase 2 meeting with the U.S. FDA which has provided a clear and achievable path to a New Drug Application in the โฆSee details»
Cold sore prevention biotech Squarex withdraws $15 million IPO
May 19, 2023 Squarex's primary candidate, SQX770, was able to cut the number of cold sore outbreaks by 2.6-fold in the period from 42 to 120 days after a single topical dose on the arm โฆSee details»
Squarex Pharma Signs Investment Term Sheet for Up to $75
Dec 7, 2021 Joseph Cunningham, CFO, Squarex Pharma Tel 612 787-7281 [email protected]. Joseph Cunningham Squarex Pharma +1 612-787-7281 โฆSee details»
SciMed Biotech Podcast with Hugh McTavish of SquareX โฆ
Sep 19, 2024 As the founder and CEO of SquareX Pharmaceutical Corporation and IGF Oncology, Hugh shares his unique journey from facing personal health challenges to โฆSee details»
Squarex | Saint Louis Park MN - Facebook
Squarex, Birchwood. 21 likes. We are a clinical stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for prevention of recurrent cold sores...See details»
Squarex Announces Positive Results from Completed Phase 2 โฆ
ST. PAUL, Minn., Aug. 5, 2019 /PRNewswire/ -- Squarex, a clinical-stage pharmaceutical company developing a topical immunomodulator for the long-term prevention of recurrent cold โฆSee details»
Squarex Announces End of Phase 2 Meeting with FDA for its Cold โฆ
About Squarex Pharma Squarex is a clinical stage pharmaceutical company which has developed a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of โฆSee details»
Squarex Announces Publication of Clinical Results for SQX770 for โฆ
Feb 14, 2019 Squarex is a clinical-stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester (SQX770) for the prevention of โฆSee details»
Cold sore prevention biotech Squarex Pharmaceutical files for a โฆ
Jan 17, 2023 Squarex Pharmaceutical, a Phase 2 biotech developing a topical therapy for cold sores, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. In its โฆSee details»
A phase 2, multicenter, placebo-controlled study of single
Electronic address: [email protected]. PMID: 32289388 DOI: 10.1016/j.jaad.2020.04.021 No abstract available. Publication types Clinical Trial, Phase II โฆSee details»